The avian Rev-T retrovirus encodes the v-Rel oncoprotein, which is a member of the Rel/NF-kB transcription factor family. v-Rel induces a rapidly fatal lymphoma/ leukemia in young birds, and v-Rel can transform and immortalize a variety of avian cell types in vitro. Although Rel/NF-kB transcription factors have been associated with oncogenesis in mammals, v-Rel is the only member of this family that is frankly oncogenic in animal model systems. The potent oncogenicity of v-Rel is the consequence of a number of mutations that have altered its activity and regulation: for example, certain mutations decrease its ability to be regulated by IkBa, change its DNA-binding site speci®city, and endow it with new transactivation properties. The study of v-Rel will continue to increase our knowledge of how cellular Rel proteins contribute to oncogenesis by aecting cell growth, altering cell-cycle regulation, and blocking apoptosis. This review will discuss biological and molecular activities of v-Rel, with particular attention to how these activities relate to structure ± function aspects of the Rel/NF-kB transcription factors.
Introduction v-rel is the oncogene of the avian Rev-T (reticuloendotheliosis virus strain T) retrovirus that was isolated from the liver of a diseased adult turkey in a Kansas ock in 1958 by Theilen and Robinson (Robinson and Tweihaus, 1974; Sevoian et al., 1964; Theilen et al., 1966) . For some years thereafter, the study of Rev-T was the somewhat esoteric endeavor of relatively few laboratories. In part, this was no doubt attributable to the membership of Rev-T in a class of avian viruses, the reticuloendotheliosis viruses, which was distinct from the more commonly studied avian leukosis viruses. Of course, interest in Rev-T was peaked in the late 1980's when it was found that v-Rel shared extensive sequence similarity with the Dorsal protein of Drosophila melanogaster and subunits of the mammalian NF-kB transcription factor. This review will cover critically what is known about the activities and pathogenesis of the v-Rel transcription factor, which has been selected as a potently and uniquely oncogenic member. For related information and a historical perspective on this subject, the reader may wish to consult several previous reviews (Bose, 1992; Enrietto, 1990; Gilmore, 1991 Gilmore, , 1992 Gilmore et al., 1995 Gilmore et al., , 1996 Hannink and Temin, 1991; Kabrun and Enrietto, 1994; Moore and Bose, 1998a; Rice and Gilden, 1988; Temin, 1990) .
Structures of Rev-T and v-Rel
As with all highly oncogenic retroviruses, the genomic structure of Rev-T is the result of a recombination event between a replication-competent retrovirus and cellular sequences. In this case, the recombination event was between the avian Rev-A helper virus and turkey c-rel genomic sequences ( Figure 1 ). As a consequence, turkey c-rel sequences from exons two through ten have replaced most of the Rev-A env gene and there has been a deletion of gag and pol sequences in Rev-T (Capobianco and Gilmore, 1991; Capobianco et al., 1990; Chen and Temin, 1982; Chen et al., 1981 Chen et al., , 1983 Hu et al., 1981; Rice et al., 1982; Stephens et al., 1983; Wilhemlsen and Temin, 1984; Wilhelmsen et al., 1984; Wong and Lai, 1981) . Therefore, v-rel is an env ± rel ± env fusion gene and is the sole gene of Rev-T. The deletion of gag and pol sequences in Rev-T appears to have been selected to ensure suciently high-level expression of v-rel for malignant transformation (Chen and Temin, 1982; Miller and Temin, 1986; Miller et al., 1988) .
The 5' env ± rel fusion in v-rel is in-frame, but the 3' rel ± env fusion is out-of-frame: thus, the 503 amino acid (aa) v-Rel protein contains 11 N-terminal Env aa, 464 c-Rel-derived aa, and 18 out-of-frame Env aa at its C terminus (Capobianco et al., 1990; Stephens et al., 1983; Wilhelmsen et al., 1984) . Due to single nucleotide changes, the 11 N-terminal Env aa of v-Rel have three substitutions at aa 3, 6 and 9 as compared to the Nterminal aa of Rev-A Env. The 18 out-of-frame env codons for the C terminus of v-Rel have 4 nucleotide substitutions as compared to the Rev-A env sequence, creating 4 aa changes in the out-of-frame Env aa as compared to the wild-type Env sequence. Finally, within the Rel-derived aa, there are 17 dierences between v-Rel and turkey c-Rel: namely, 14 substitutions and 3 deletions (Wilhemlsen et al., 1984) . Because most comparative functional studies of v-Rel and c-Rel have been performed with chicken c-Rel, I note here that a comparison of v-Rel and chicken c-Rel reveals 15 additional changes between v-Rel and c-Rel (Capobianco et al., 1990) . In short, the Env ± Rel ± Env v-Rel protein is a highly mutated form of what was likely the original tripartite Rev-A Env ± turkey cRel ± Env recombinant (Figure 2 ).
v-Rel as a member of the Rel/NF-kB family of transcription factors
The cellular Rel/NF-kB family includes ®ve vertebrate proteins (p50/p105, p52/p100, c-Rel, RelA/p65, and RelB) and three Drosophila proteins (Dorsal, Dif and Relish) . These proteins comprise a family due to their extensive structural similarity within a domain of approximately 300 aa called the Rel homology (RH) domain. In addition, most Rel/NF-kB proteins are regulated by subcellular localization. Namely, they usually exist as inactive complexes in the cytoplasm, due to inhibitor (IkB) binding. These complexes can be induced by many signals to become active nuclear transcription factors (Pahl, 1999, this issue) . This signal is often transmitted by activation of a cytoplasmic IkB kinase complex whose activity promotes the ubiquitination and degradation of IkB, which liberates the Rel/ NF-kB transcription factor and allows it to enter the nucleus.
The RH domain is located towards the N-terminal half of all Rel/NF-kB transcription factors and it contains sequences essential for the formation of homo-and heterodimers, DNA binding, IkB binding, and nuclear localization. In many cases, sequences Cterminal to the RH domains of Rel/NF-kB proteins contain transactivation domains, which are less conserved than sequences within the RH domain. If one superimposes v-Rel on this common structural organization, one sees that v-Rel has an intact RH domain (containing 7 mutations in 273 aa as compared to c-Rel) but a truncated and more highly-mutated Cterminal domain (10 mutations in 187 aa; Figure 2 ).
Eects of v-Rel and mutants of chicken c-Rel on cellular growth, lifespan, and the control of apoptosis
In vivo hematopoietic diseases As mentioned above, Rev-T is the replication-defective member of the reticuloendotheliosis class of retroviruses that also includes the replication-competent spleen necrosis virus (SNV), duck infectious anemia virus, chick syncytial virus (CSV) and Rev-A (Purchase et al., 1973; Purchase and Witter, 1975) . The reticuloendotheliosis viruses are more closely related to mammalian retroviruses than to the avian leukosis viruses (Barbacid et al., 1979; Charman et al., 1979; Hunter et al., 1978; Maldonado and Bose, 1971; Wilhelmsen et al., 1984) . The original Rev-T isolate was a pseudotyped Rev-T(Rev-A) mixture. However, Rev-T can also be pseudotyped with CSV and SNV, and replication-competent Rous sarcoma virus-derived expression vectors for v-rel have also been created (Morrison et al., 1991) .
The replication-competent reticuloendotheliosis viruses can themselves cause a variety of diseases in infected birds. Most notably, Rev-A can induce an acute atrophy of the bursa and thymus, immunosuppression, and a`runting' syndrome in which infected chicks are noticeably smaller than uninfected birds (Mussman and Twiehaus, 1971; Rup et al., 1979; . In addition, after a long latency, Rev-A and CSV can induce bursal lymphomas in chickens (Witter and Crittenden, 1979; Witter et al., 1981) , due to proviral integration and activation of cmyc (Noori-Daloii et al., 1981; Swift et al., 1985) .
The original isolate of Rev-T came from a turkey with liver lesions that were no doubt lymphomas. The Figure 2 Comparison of the structures of v-Rel oncoprotein and avian c-Rel proto-oncoproteins. Shown are the generalized structures of v-Rel and avian c-Rel. v-Rel has a 2 aa N-terminal deletion and 118 aa C-terminal deletion as compared to chicken cRel; in place of these c-Rel aa; v-Rel has 11 N-terminal Env-derived aa (with three aa substitutions as compared to the Rev-A Env) and 18 out-of-frame Env aa at its C terminus (with four alterations due to base changes). Env-derived aa of v-Rel, horizontal hatching; c-Rel aa not in v-Rel, diagonal hatching; Env, aa at the analogous positions in Rev-A Env. The approximate positions of residues corresponding to internal dierences between v-Rel and the turkey and chicken c-Rel proteins are indicated; for precise positions of these changes, the reader is referred to Capobianco et al. (1990) and Wilhelmsen et al. (1984) . At the bottom are indicated the approximate extents of the Rel Homology domain, which contains sequences important for DNA binding, dimerization, nuclear localization, and interaction with inhibitor protein IkBa, and of the C-terminal transactivation domains original virus stock was serially-passaged over 300 times through young chickens and turkeys (Mussman and Twiehaus, 1971; Robinson and Tweihaus, 1974; Theilen et al., 1966) during which the oncogenicity of the virus increased (Rice and Gilden, 1988; Robinson and Tweihaus, 1974) . As such, v-rel is now no doubt the most potent oncogene: high titer virus stocks containing v-rel are extremely lethal agents, and young chickens infected with such stocks succumb within 7 ± 14 days with nearly 100% eciency.
Rev-T(Rev-A) stocks of virus do not seem to be transmitted horizontally among chickens (Peterson and Levine, 1971) . In most in vivo v-Rel oncogenicity experiments, virus stocks are injected intraperitoneally into 1 ± 3 day-old birds. Young chickens infected with Rev-T virus stocks rapidly develop polyclonal tumors primarily in the spleen and, to a lesser extent, in the liver and other tissues (Olson, 1967; Robinson and Tweihaus, 1974; Sevoian et al., 1964; Olson, 1971, 1973a,b) . Tumor cells from these animals are heterogeneous, and the in vivo disease caused by vrel can vary according to the species (e.g., chickens, turkeys, ducks, geese, pheasants, or Japanese quails), the age of the bird, and possibly the helper virus used (Larose and Sevoian, 1965; Taylor and Olson, 1972; Theilen et al., 1966) . For example, Rev-A induces greater bursal cell toxicity than CSV (Barth and Humphries, 1988a; Witter et al., , 1981 , and Humphries and colleagues have reported that Rev-T(Rev-A) stocks yield primarily T-cell and myeloid tumors, whereas Rev-T(CSV) stocks yield primarily Bcell tumors (Barth and Humphries, 1988a,b; Barth et al., 1990) . However, some of the tumor cell dierences may have also been due to a B-cell transforming variant of v-rel used in those experiments (Romero and Humphries, 1995; see below) .
Although mutations frequently occur in Rel/NF-kB/ IkB genes in human cancers (Rayet and GeÂ linas, 1999 , this issue), v-Rel is the only Rel/NF-kB family protein that has been shown to be oncogenic in mammals. Carrasco et al. (1996) generated transgenic mice in which v-rel was placed under the control of the T cellspeci®c lck promoter. Between 4 and 10 months of age, these animals developed a disease strikingly similar to that seen (albeit more rapidly) in Rev-T-infected chickens: multiple lymphomas in enlarged spleens and livers. These mouse tumors consisted primarily of immature T cells and were oligoclonal. However, these tumor cells were not highly malignant, in that they could not be serially transplanted into syngeneic mice and they grew poorly and required IL-2 for growth in vitro. The long latency required for the vRel-induced tumors to appear in transgenic mice suggests that other mutations occurred in the tumor cells. That other genetic changes can in¯uence the oncogenicity of v-Rel in mammals was convincingly shown by crossing the v-rel transgenic mice to NF-kB p50/p105 knockout mice, which led to the development of neoplastic disease with a much shorter latency (Carrasco et al., 1996) .
In vitro transformation of avian hematopoietic cells vRel can also transform a variety of cell types when primary chicken spleen or bone marrow cultures are infected in vitro (Hoelzer et al., 1980) . Moreover, vRel-transformed cell lines, established by in vitro infection of chicken spleen cells and which do not shed helper virus, can induce fatal tumors with as few as 100 cells when injected into histocompatible chickens (Lewis et al., 1981) . Cells transformed in vitro by v-Rel have been reported to have characteristics of immature pre-B/pre-T cells (Beug et al., 1981; Chen et al., 1988; Morrison et al., 1991; Zhang et al., 1989) , abnormal B cells (Chen et al., 1988) , immature and mature B cells (Benatar et al., 1991 (Benatar et al., , 1992 Boehmelt et al., 1995; Keller et al., 1979; Lewis et al., 1981; Sasaki and Koyama, 1989; Shibuya et al., 1982; Zhang et al., 1991) , T cells (Barth et al., 1990; Marmor et al., 1993; Schat et al., 1992) , myeloid cells (Barth et al., 1990; Morrison et al., 1991) , erythroid cells (Morrison et al., 1991) , and pre-dendritic cells (Boehmelt et al., 1995) .
Several experimental variables are likely to account, at least in part, for these dierent reports. First, as discussed above, dierent transformed cell types may arise due to dierences in the helper virus used to pseudotype the v-rel vector. Second, the level of expression of v-rel from the vector may aect the transforming spectrum observed: for example, a replication-competent vector for the expression of vrel appears to transform distinct bone marrow-derived cell types in vitro (Morrison et al., 1991) . Third, in some experiments, slightly dierent variants of v-rel may have been used; v-Rel proteins that dier only at aa 40 preferentially transform B cells (Romero and Humphries, 1995) . Fourth, the age of the chicken from which bone marrow or spleen cells were taken can aect the transformed cell types seen (Zhang et al., 1989 (Zhang et al., , 1991 . Fifth, v-Rel-transformed cells can undergo continued dierentiation after establishment in vitro (Zhang et al., 1989) . Sixth, in some cases, only very few in vitro-transformed colonies were analysed, which may have under-or mis-represented the cell-type transforming potential of v-Rel. Seventh, the culture conditions may aect the transformed cell phenotype: for example, fetal serum lots can greatly aect the in vitro transforming eciency of v-Rel (C GeÂ linas and TD Gilmore, unpublished) and v-Rel-transformed cells may secrete factors that aect their growth properties .
Nevertheless, taken together, these experiments establish that v-Rel is a highly versatile hematopoietic cell transforming agent, and its potential use in characterizing avian hematopoietic cell dierentiation has probably not been ful®lled.
Transformation of avian ®broblasts by v-Rel
Although the primary transforming activity of v-Rel is directed towards hematopoietic cells, v-Rel can malignantly convert avian ®broblasts by several criteria and v-Reltransformed chicken embryo ®broblasts (CEF) can induce sarcomas when injected into the wing web of chickens (Franklin et al., 1974 (Franklin et al., , 1977 Hoelzer et al., 1979; Kralova et al., 1994; Moore and Bose, 1988b; Morrison et al., 1991 Morrison et al., , 1992 . v-Rel-transformed CEF show an enlarged and cuboidal morphology, can form foci on monolayers and colonies in soft agar, and show actin micro®lament disorganization. However, many of these v-Rel-induced changes are quite weak or take a long time to occur. In a limited survey, there appears to be a correlation between the ability of v-Rel mutants to transform CEF and chicken lymphoid cells (Morrison et al., 1992) , suggesting that the activities needed for transformation of both cell types are the same.
v-Rel extends the lifespan of chicken cells in culture and inhibits apoptosis v-Rel is an ecient immortalizing agent for avian hematopoietic cells and can greatly extend the lifespan of CEF in culture. That is, greater than 90% of v-Rel-transformed spleen cell or bone marrow colonies can usually be propagated for extended periods of time (4 ± 6 months) or sometimes inde®nitely in vitro, and v-Rel-expressing CEF survive approximately 3 ± 4 times longer than normal CEF in culture (Kralova et al., 1994; Moore and Bose, 1988b; Morrison et al., 1991) .
The ability of v-Rel to immortalize avian hematopoietic cells in vitro is likely to be due to its ability to block apoptosis. Neiman et al. (1991) demonstrated that v-Rel-transformed tumor cells show increased resistance to apoptosis induced by UV irradiation or cell dispersal. That this block to apoptosis was due to a direct action of v-Rel has been shown by experiments using conditional mutants or conditional expression of v-Rel White and Gilmore, 1993; White et al., 1995; Zong et al., 1997) . For example, chicken spleen cells transformed by temperature-sensitive v-Rel mutants undergo apoptosis when shifted to the non-permissive temperature . Overexpression of Bcl-2, but not the caspase inhibitor CrmA, can block the appearance of DNA ladders in these cells, suggesting that v-Rel may, at least in part, immortalize cells through a Bcl-2-related pathway . v-Rel does not, however, directly activate the bcl-2 gene itself Zong et al., 1997) . However, v-Rel has recently been shown to enhance expression of the gene encoding the Bcl-2-like protein Nr13, which is associated with blocking bursal cell apoptosis (Lee et al., 1999) , and c-Rel can activate the gene encoding the Bcl-2-related protein A1 (Grumont et al., 1999; Zong et al., 1999) . In addition, v-Rel-transformed cells show increased expression of an IAP, inhibitor of apoptosis, gene (You et al., 1997) . Nevertheless, most of the proposed target genes for the cellular Rel/NF-kB-induced block to apoptosis (Barkett and Gilmore, 1999, this issue) have not been investigated as direct targets for v-Rel.
It is not known whether the transforming and immortalizing activities of v-Rel are one and the same. That is, conditionally-transformed spleen cells both undergo apoptosis and cease proliferating when shifted to non-permissive conditions Zong et al., 1997) . Therefore, it is not clear whether v-Rel actively blocks apoptosis by, for example, increasing the expression of anti-apoptotic genes (as discussed above) or by providing a dierentiation-blocking or proliferative signal that prevents avian lymphoid cells from undergoing apoptosis. The analysis of several v-Rel mutants shows a strict correlation between their abilities to transform chicken spleen cells and block apoptosis in HeLa cells, suggesting that the two activities are related Zong et al., 1997 Zong et al., , 1998 . However, v-Rel is not mitogenic in HeLa cells. Moreover, several reports have identi®ed v-Rel mutants that can induce the appearance of transformed chicken lymphoid colonies in vitro, but that are greatly impaired in their ability to immortalize cells Gilmore and Temin, 1988; Hannink and Temin, 1989; Mosialos et al., 1991; Sachdev et al., 1997; Sachdev and Hannink, 1998; Sylla and Temin, 1986) . Therefore, the transforming and immortalizing activities of v-Rel may both depend on, for example, the ability of v-Rel to increase gene expression, but the sets of genes that cause each eect may be distinct or partially overlapping. In addition, it appears that there are cellular factors that aect the ability of v-Rel to immortalize avian lymphoid cells (Marmor et al., 1993) .
Malignant transformation by c-Rel mutants
The chicken c-Rel protein is a 68 kDa polypeptide (Simek and Rice 1988b) . Overexpression of full-length chicken c-Rel can be (weakly) transforming in avian lymphoid cells and in CEF (Abbadie et al., 1993; Gilmore et al., 1995; HrdlickovaÂ et al., 1994b; Kralova et al., 1994) . Moreover, in one chicken B-cell lymphoma line, a retroviral promoter insertion has activated expression of full-length c-rel (Kabrun et al., 1990) . However, several experiments indicate that C-terminal truncations can increase the oncogenicity of chicken c-Rel in vitro and in vivo. First, planned deletions of C-terminal sequences of chicken c-Rel render it more transforming that intact c-Rel in spleen cell transformation assays HrdlickovaÂ et al., 1994b; Kamens et al., 1990; Nehyba et al., 1994 Nehyba et al., , 1997 and for CEF transformation (Abbadie et al., 1993; Kralova et al., 1994) . Second, the rare transformed colonies that arise after infection of chicken spleen cells with retroviral vectors carrying full-length c-rel often express C terminally-truncated c-Rel proteins . Third, C terminally-truncated c-Rel proteins are similarly selected in in vivo tumorigenicity assays in chicken (HrdlickovaÂ et al., 1994b) . However, whether there are other (e.g., internal) mutations in these selected c-rel transforming genes has not been determined. Furthermore, it is important to remember that these c-rel truncation experiments do not precisely mimic the generation of the v-rel gene in the original Rev-T isolate. That is, the original recombination event between Rev-A and cellular c-rel sequences likely generated an isolate of Rev-T that had an env ± rel ± env fusion gene which contained wild-type env and rel sequences upon which further oncogenic selection was then imposed.
The latter point is especially relevant in the interpretation of experiments which have attempted to map mutations in v-rel that have contributed to its oncogenicity. The simple summary of experiments that have looked at the eect on transformation of mutations that revert v-Rel aa to those of c-Rel or of chimeric v-Rel/c-Rel proteins is that the interpretations are not simple. For example, although the deletion of approximately 50 C-terminal aa from wild-type chicken c-Rel is sucient to create a fairly eective and stable transforming protein HrdlickovaÂ et al., 1994b; Kamens et al., 1990) , the deletion or mutation of the 11 N-terminal Env aa of v-Rel greatly reduces its transforming eciency (Bhat and Temin, 1990; . Similarly, reciprocal C/V and V/C chimeric proteins are each much less transforming than wild-type v-Rel or sometimes less transforming than C-terminally-truncated, but other-wise wild-type, c-Rel proteins. Nevertheless, it is clear that no single aa dierence between v-Rel and c-Rel is essential for oncogenicity (Bhat and Temin, 1990; Hannink and Temin, 1989; HrdlickovaÂ et al., 1994b; Nehyba et al., 1994 Nehyba et al., , 1997 Sachdev and Hannink, 1998; Sylla and Temin, 1986) and that the mutations that have occurred in v-Rel act cooperatively to enable its potent transforming activity (HrdlickovaÂ et al., 1994b) .
v-Rel is cytotoxic in many mammalian cells in culture Although v-Rel can be readily expressed at high levels in chicken, turkey and quail ®broblasts, the characterization of the eects of v-Rel on mammalian cells has been stymied by the cytotoxicity of high-level expression of v-Rel in many mammalian cell types. The cytotoxicity of high-level expression of v-Rel has been seen in mouse and rat ®broblasts and mouse B-cell lines (GeÂ linas Hannink and Temin, 1989; Schwartz and Witte, 1988) . Thus, one strategy to study v-Rel eects in mammalian cells has been to use inducible promoters (Zong et al., , 1998 .
Very little is known about the mechanism by which v-Rel exerts its cytotoxic eect; however, the cytotoxic eects of v-Rel mutants in mammalian cells generally correlate with their transforming activities in avian lymphoid cells (GeÂ linas Hannink and Temin, 1989) . This suggests that v-Rel promotes toxicity by binding to DNA and aecting gene expression (see below). Overexpression of chicken cRel can induce G 1 -S phase cell-cycle arrest in HeLa cells and CEF Zurovec et al., 1998) , and this could also be the mechanism by which v-Rel is toxic. However, the cytotoxicity of v-Rel in mammalian cells has not been investigated in any comprehensive way, and it appears that at least one mammalian cell type, D17 dog osteosarcoma cells, can tolerate high-level expression of v-Rel (TD Gilmore, 1999 unpublished results) . The analysis of mammalian cells resistant to the cytotoxicity of v-Rel could lead to the genetic identi®cation of factors required for or capable of blocking this eect.
Subcellular localization of v-Rel and chicken c-Rel
v-Rel is a 59 kDa protein in cells (Garson and Kang, 1986; Gilmore and Temin, 1986; Herzog and Bose, 1986; Rice et al., 1986; Walro et al., 1987) . Surprisingly, one of the more complicated issues surrounding v-Rel is its subcellular localization, especially as it relates to its transforming activity in dierent cell types. From early studies, it was quite clear that overexpressed v-Rel is primarily a nuclear protein in CEF and primarily a cytoplasmic protein in transformed chicken spleen cells (Gilmore and Temin, 1986; Simek et al., 1986; Walro et al., 1987) .
Like other Rel/NF-kB proteins, v-Rel has a conserved nuclear localizing sequence (NLS) at the C terminus of the RH domain, but it also contains a second NLS, which has not yet been precisely identi®ed, in its non-conserved C-terminal half (Gilmore and Temin, 1988) . Therefore, mutations that alter or delete the conserved RH domain NLS only partially disrupt nuclear localization of v-Rel in CEF (Gilmore and Temin, 1988; . Moreover, such NLS mutations do not aect the transforming function of v-Rel, and if anything, enhance its cytoplasmic localization in transformed lymphoid cells (Gilmore and Temin, 1988; Rottjakob et al., 1996; . On the other hand, the addition of the strong NLS of the SV40 large Tantigen to v-Rel also does not aect the transforming function of v-Rel, but lymphoid cells transformed by such mutants show an exclusively nuclear pattern of v-Rel staining (Gilmore and Temin, 1988) . As such, one might propose, as early studies did, that the subcellular localization of v-Rel is irrelevant to its transforming activity. However, such an interpretation is obviously incompatible with the many studies indicating that DNA binding is essential for v-Rel's transforming function (see below).
A resolution to this paradox comes from studies that have kinetically looked at localization of v-Rel in dierent cell types; these studies suggest that it is misleading to analyse the static localization of v-Rel. Sachdev and Hannink (1998) have recently shown that the primarily cytoplasmic localization of v-Rel in transformed chicken lymphoid cells is the consequence of a rapid nuclear export of v-Rel mediated by IkBa. Moreover, due to two mutations in the central portion of v-Rel (aa Ser-295 and Pro-311 in v-Rel), the v-Rel NLS is not eciently masked by IkBa (Sachdev and Hannink, 1998) . Thus, v-Rel is continually shuttling into and out of the nucleus in transformed chicken lymphoid cells, whereas c-Rel is constitutively maintained in the cytoplasm due to a masking of its NLS by IkBa. That the, presumably transient, nuclear localization of v-Rel is essential for transformation is indicated by the greatly reduced transforming eciency of a v-Rel mutant which has an increased nuclear export eciency due to the addition of a strong nuclear export sequence (Sachdev et al., 1997) . It is likely, therefore, that the ability of v-Rel mutants with deletions of the RH domain NLS to transform cells arises from the ability of the second, C-terminal NLS to direct sucient nuclear localization.
The subcellular localization of introduced v-Rel also progressively varies within a cell due to its ability to increase expression of the genes encoding IkBa and p100. That is, shortly after infection of avian spleen cells, the majority of v-Rel is located in the nucleus, but as it activates IkBa and p100 expression, these proteins interact with v-Rel and cause increased cytoplasmic localization of v-Rel (HrdlickovaÂ et al., 1995b) . Long-term culturing of v-Rel-expressing CEF has also been reported to lead to increased cytoplasmic localization of v-Rel (Moore and , presumably also due to increased expression of IkB proteins.
Taken together, these studies suggest that a certain level of v-Rel must enter the nucleus to transform cells and that, at least in part, mutations in v-Rel that decrease its association with IkBa have enhanced the ability of v-Rel to reside in the nucleus and transform cells. Nevertheless, v-Rel can still be partially maintained in the cytoplasm by interaction with IkB proteins, such as IkBa, p100 and p105.
DNA binding by v-Rel
All Rel/NF-kB proteins bind DNA as dimers and the composition of these dimers determines their DNA target sequence speci®city (see Chen and Ghosh, 1999, this issue) . It is well-established that v-Rel must bind DNA in order to transform cells: the analysis of numerous mutations within the RH domain of v-Rel shows a strict correlation between the ability of v-Rel to bind DNA (and/or form dimers) and to transform cells (Ballard et al., 1990; Kumar et al., 1992; Morrison et al., 1992; Mosialos and Gilmore, 1993; Mosialos et al., 1991; White and Gilmore, 1993; Walker et al., 1992) . To cite one convincing example, several mutations within the RH domain that lessen, but do not abolish, the ability of v-Rel to bind DNA, correspondingly lessen its ability to transform cells (Mosialos and Gilmore, 1993; Mosialos et al., 1991) .
Although v-Rel can interact with cellular Rel/NF-kB factors in vivo and in vitro (see below, Table 2 ), it appears that v-Rel homodimers are the important eector complexes for the transformation of both avian cells and mammalian cells. Mutations within the RH domain that inhibit the ability of v-Rel to form homodimers, but do not aect its ability to form heterodomers with p52 and p50, abolish the transforming activity of v-Rel (Kamens et al., 1990; Mosialos and Gilmore, 1993; Mosialos et al., 1991; Walker et al., 1992; . However, the transforming function of one such v-Rel homodimerization-defective mutant can be partially restored by overexpression of chicken NF-kB p52 . This indicates that the DNA target sites, and presumably genes, that are essential for transformation by v-Rel can be bound by both v-Rel homodimers and v-Rel ± p52 heterodimers, assuming these complexes are present at sucient levels in the cell. Moreover, Romero and Humphries (1995) showed that the speci®c aa at residue 40 within the RH domain can aect both DNA binding and target cell transformation: when an Ala residue is present at aa 40 v-Rel has a preference for transforming T and non-B/non-T lymphoid cells, whereas a Ser at aa 40 gives v-Rel a preference for transforming B cells. Furthermore, the Ser-40 B-cell transforming v-Rel variant has an increased ability to bind DNA in vitro. Thus, one might presume that distinct anities of v-Rel dimers for DNA target sites aect the speci®c genes that are activated (or repressed) or the level of activation (or repression) of these genes in a manner that aects transformation. Lastly, Carrasco et al. (1996) showed that the T-cell tumors that develop in transgenic mice in which v-rel is controlled by a T cell-speci®c promoter contain v-Rel homodimers and v-Rel ± p50 heterodimers, but that these mice develop T-cell tumors more rapidly when they are crossed to mice with a knockout of the gene encoding p50. This ®nding suggests that v-Rel homodimers are the most eective transforming complexes in these mice; however, it cannot be ruled out that the lack of p50 simply lessens the immune response of these mice to the v-Rel-initiated tumors. Furthermore, the crossing of ikba transgenic mice to vrel transgenic mice, extends the lifespan of the v-rel transgenic mice and changes the course of the T-cell disease, primarily by inhibiting the DNA-binding activity of p50 ± v-Rel heterodimers, but not v-Rel homodimers (Carrasco et al., 1997) .
Several mutations appear to alter the DNA-binding properties of v-Rel as compared to c-Rel. In a comprehensive study, Nehyba et al. (1997) identi®ed three mutations that aected v-Rel binding in distinct ways. First, the Thr-20 mutation in v-Rel changes the DNA-binding speci®city; that is, the Thr-20 mutation enables v-Rel to bind to kB sites of the IL-2 receptor (GGGAATTCCC) and the MHC class I gene (GGGGGTTCCC) better than c-Rel. Second, a mutation(s) near the C terminus of the RH domain increases the DNA-binding ability of v-Rel for various kB sites, possibly by increasing the stability of v-Rel homodimers. Third, a mutation(s) C-terminal to the RH domain decreases the ability of v-Rel to bind various kB sites. In addition, v-Rel and c-Rel homodimers show distinct mobility shifts on EMSAs when bound to certain kB probes (Epinat and Gilmore, unpublished results; Nehyba et al., 1997) . Lastly, the two mutations in v-Rel (aa Ser-295 and Pro-311 in vRel) that abolish the interaction of its NLS with IkBa also reduce the ability of v-Rel to be removed from DNA by IkBa (see above; Sachdev and Hannink, 1998) .
Many of the studies described above comparing the DNA-binding properties of Rel proteins were performed with in vitro-synthesized Rel proteins, and it is important to remember that v-Rel exists in multiple and dynamic DNA-binding complexes in cells (Hodgson and Enrietto, 1995; HrdlickovaÂ et al., 1995a; Kabrun et al., 1991; Kochel and Rice, 1992) . Transactivation by v-Rel C-terminal transactivation domains The C-terminal deletion in v-Rel removes a strong transactivation domain of c-Rel (Kamens et al., 1990; Richardson and Gilmore, 1991) . Nevertheless, when fused to GAL4 or LEXA DNA-binding domains, sequences in the Cterminal half of v-Rel can function as transactivation domains, albeit about 50-fold less eciently than the intact C-terminal sequences of c-Rel (Richardson and Gilmore, 1991) . Deletion analyses suggest that there are at least two transactivation domains in the Cterminal half of v-Rel (Sarkar and Smardova et al., 1995) . A C-terminal deletion that removes all transactivation activity of v-Rel also abolishes its ability to transform spleen cells. However, deletions that remove parts of either transactivation domain reduce, but do not abolish, transforming activity Sarkar and Gilmore, 1993; Smardova et al., 1995) . Furthermore, the addition of non-Rel sequences at the C terminus of v-Rel can inhibit the C-terminal transactivation domain of v-Rel and render v-Rel non-transforming . Taken together, these results have led to the hypothesis that v-Rel must activate transcription in order to transform cells. Nevertheless, there are data which challenge this dogma: (1) in transformation assays, the C-terminal transactivation domains of v-Rel cannot be replaced by heterologous transactivation domains ; (2) at least one point mutation in the C-terminal transactivation domain of v-Rel abolishes the transforming ability of v-Rel but does not reduce its transcription activation function ; and (3) the C terminus of v-Rel (and chicken c-Rel) share essentially no sequence similarity with C-terminal domains of mammalian c-Rel proteins (Capobianco et al., 1990) . These results indicate either that the extent of transcriptional activation by v-Rel must fall within a narrow range or that there is an additional or alternative function within the C-terminal sequences of v-Rel that is essential for its transforming activity.
It is not precisely known how the C-terminal sequences of v-Rel activate transcription. However, these sequences have been shown to directly interact with TATA box-binding protein and TFIIB of the general transcription complex (Xu et al., 1993) . Of note, the C-terminal transactivation domain of v-Rel does not function in the yeast S. cerevisiae, suggesting that a co-activator for v-Rel transactivation may not be available in yeast. Recently, a two-hybrid screen has identi®ed Trip6 as a possible co-activator for v-Rel (Koedood Zhao et al., 1999) ; Trip6 was previously identi®ed as interacting with the thyroid hormone receptor transcription factor in a ligand-dependent fashion (Lee et al., 1995) .
The analysis of transcriptional activation by fulllength v-Rel in its vertebrate target cells for transformation is not a simple task. For example, because v-Rel is a relatively weak activator of transcription, high-level expression of v-Rel reduces transcription from kB site-containing promoters in cells that have constitutively nuclear kB-site activating complexes (Inoue et al., 1991; Ishikawa et al., 1993; McDonnell et al., 1992; Richardson and Gilmore, 1991; Walker et al., 1992) . That is, v-Rel homodimers displace more strongly activating complexes, such as ones containing RelA or c-Rel, and reduce the level of transcription. Moreover, because v-Rel can form heterodimers with endogenous Rel proteins and transcriptionally activate their genes, the analysis of eects of v-Rel on kB site-containing promoters can become somewhat muddled in vertebrate cells. Therefore, many experiments that have investigated transcriptional activation of kB site promoters by v-Rel have been performed in cell types that lack endogenous Rel proteins, such as in yeast, Drosophila cells, mouse F9 teratocarcinoma cells or human Tera-2 embryonal carcinoma cells, all of which lack endogenous kB sitebinding activity Inoue et al., 1991; Ishikawa et al., 1993; Kamens and Brent, 1991; Mosialos and Gilmore, 1993; Sachdev et al., 1997) .
N-terminal transactivation Even before the homology of v-Rel to NF-kB was known, it was suggested that vRel might be a transcription factor based on the ability of LEXA ± v-Rel proteins to activate transcription in yeast (Kamens et al., 1990) . Curiously, those early experiments mapped the v-Rel transactivation domain to sequences within the N-terminal half of v-Rel (that is, aa 1-331, containing the N-terminal Env sequences and the RH domain). Recently, it has been shown that GAL4 fusion proteins containing these N-terminal sequences of v-Rel can activate transcription in yeast and in CEF, whereas the analogous sequences from chicken c-Rel cannot (Epinat et al., 1999) . The ability of aa 1-331 of v-Rel to activate transcription is dependent on the 11 N-terminal mutant Env aa in vRel; that is, a v-Rel mutant with the corresponding Rev-A helper virus Env aa cannot activate transcription (Epinat et al., 1999) . However, the v-Rel mutant Env aa do not constitute an independent transactivation domain, as sequences within the RH domain are also required for transactivation (Epinat et al., 1999; Kamens et al., 1990) . This function of v-Rel also correlates with its transforming function in that reversion of the N-terminal Env aa to those of Rev-A reduces the transforming ability of v-Rel by tenfold (Bhat and Temin, 1990 ) and the deletion of the Env aa from v-Rel also greatly impairs its transforming ability (Bhat and Temin, 1990; . Taken together, these results suggest that the mutant Env aa in v-Rel expose a transactivation domain within the RH domain, and that these mutations were selected based on their ability to enhance the transforming function of v-Rel. Transactivation functions within the RH domain have also been described for p50 (Fujita et al., 1992) and an oncogenic form of p52/p100 found in human HUT-78 lymphoma cells (Chang et al., 1995; Epinat et al., 1999) .
The ability of sequences in the N-terminal half of vRel to activate transcription when brought to DNA through a heterologous DNA-binding domain (such as that of GAL4) may mimic interactions that occur in cells. Sequences within the RH domain have been shown to have the ability to activate transcription when brought to DNA through interaction with cellular transcription factors NF-kB p50 and Sp1 (Sif and Gilmore, 1994; Xu and GeÂ linas, 1997) . However, the relevance of these activities to transformation is unclear.
Cellular target genes for regulation by v-Rel A number of genes whose expression is altered by v-Rel expression have been identi®ed (Table 1 ). The expression of most of these genes is increased after expression of v-Rel, although in general many of the studies have been designed to identify up-regulated genes. Several of these genes have upstream kB sites, suggesting they are direct targets for v-Rel. However, other genes may be indirectly aected by v-Rel, and vRel is capable of aecting gene expression by a kB siteindependent fashion (Capobianco and Gilmore, 1991; .
One might expect that v-Rel would aect the expression of genes involved in proliferation, blocks to apoptosis, immune regulation, and cell ± cell adhesion. Furthermore, in some cases, v-Rel-regulated genes might have dual roles in the process of transformation; for example, up-regulation of cytokines and/or their receptors may provide both a proliferative and cell survival signal. Indeed, many of the v-Rel-modulated genes do fall into the predicted types of classes: transcription factors and/or oncoproteins (HGM-14b, c-jun, c-fos, fra-2, c-rel, nfkb1, nfkb2, c-myb); cytokines and receptors (IL-6, IL-2Ra, MIP1b); cell surface and/or adhesion molecules (DM-GRASP; p75, Sca-2, MHC); and genes involved in apoptosis (IL-2Ra, Ch-IAP1). It is likely that many more genes will be identi®ed, as dierential screening approaches have isolated approximately 50 other vRel-aected cDNAs (Petrenko et al., 1997; You et al., 1997) .
Two types of evidence have been used to suggest that individual genes are involved in the transforming process of v-Rel: (1) that the ability of v-Rel mutants to aect expression of a speci®c gene(s) correlates with the transforming activity of the mutants, or (2) that blocking of expression of the speci®c gene(s) reverses transformation. In this regard, c-jun and c-fos, encoding the subunits of the AP-1 transcription complex, are provocative v-Rel target genes: an important kB site in the c-jun promoter is selectively bound and activated by v-Rel (due to a mutation with the RH domain) (Fujii et al., 1996, 1997) ; similarly, cfos is strongly activated by v-Rel (Kralova et al., 1998) ; and overexpression of a dominant inhibitor of c-Jun greatly reduces the ability of v-Rel to transform both spleen cells and CEF (Kralova et al., 1998) . However, the dierent target cell transforming activities of v-Rel and v-Fos or v-Jun make it clear that v-Rel does not simply chronically activate AP-1 to eect transformation. Another interesting potential target gene of v-Rel is that encoding DM-GRASP, an immunoglobulinrelated cell-surface adhesion molecule whose expression is induced by v-Rel in transformed lymphoid cells . Incubation of v-Rel-transformed cells with a monoclonal antibody to DM-GRASP reduces their rate of proliferation in vitro .
v-Rel and chicken c-Rel transforming proteins do not always induce target gene expression with the same kinetics or eciency. For example, the chicken ikba gene is preferentially activated by c-Rel (HrdlickovaÂ et al., 1995b; Schatzle et al., 1995) , whereas the c-jun and c-fos promoters are more strongly activated by v-Rel (Fujii et al., 1996 (Fujii et al., , 1997 Kralova et al., 1998) . As described above, these dierences in induction can arise from a variety of dierences between these v-Rel and cRel, including dierences in DNA binding, inhibition by IkBa, interaction with heterologous transcription factors, and transactivation.
For v-Rel, as for other nuclear oncoproteins, the identi®cation of potential target genes is much simpler than the determination of their biological relevance to transformation. As such, our understanding of the complex interplay between the hundreds of genes and proteins whose expression is likely aected in v-Reltransformed cells and of the contributions of their Lim et al., 1990 Davis et al., 1991 Capobianco et al., 1992 Simek and Rice, 1988b Morrison et al., 1989 Sif and Gilmore, 1994 Xu et al., 1993 Xu et al., 1993 Koedood Zhao et al., 1999 Gilmore and Temin, 1986 Rice et al., 1986 Tung et al., 1988b Walro et al., 1987 altered expression patterns to the transformed phenotype is meager.
Protein ± protein interactions with v-Rel
v-Rel has been demonstrated to interact with several proteins in vivo and in vitro (Table 2 ). This was ®rst apparent due to the fact that most of the v-Rel isolated from transformed chicken lymphoid cells was present in high molecular weight (approximately 300 ± 400 kDa) complexes and that immunoprecipitates of v-Rel contained a number of co-precipitating proteins (Davis et al., 1990; Kochel et al., 1991; Morrison et al., 1989; Simek and Rice, 1988a; Tung et al., 1988b) . Shortly after the homology between v-Rel and NF-kB was discovered (Kieran et al., 1990) , the major v-Rel co-precipitating proteins in vivo were identi®ed as cellular members of the Rel/NF-kB/IkB family: NFkB p105, NF-kB p100, c-Rel, and IkBa (Capobianco et al., 1990 (Capobianco et al., , 1992 Davis et al., 1991; . In addition, v-Rel is associated in transformed chicken lymphoid cells with several other unidenti®ed proteins that cross-react with certain Rel antibodies (Xu and GeÂ linas, 1995) . Furthermore, v-Rel can associate with p50 and RelA in malignant lymphocytes from transgenic mice (Carrasco et al., 1996) . In spite of the fact that much data indicate that vRel homodimers are the important eector complexes for transformation, probably less than 5% of v-Rel exists as a free homodimer in transformed avian lymphoid cells (Davis et al., 1990; Kochel et al., 1991; Morrison et al., 1989; Simek and Rice, 1988a; Tung et al., 1988b) . Although complexes containing v-Rel and p105 or p100 versus v-Rel and IkBa appear to be distinct, reports are con¯icting as to exactly how much v-Rel is in any given complex. This may be a re¯ection of the fact that dierent transformed cell types were being analysed (see above) or the conditions under which the cells were being grown. For example, treatment of cells with zinc can alter the subcellular distribution of these complexes (Storms and Bose, 1992) ; moreover, by activating transcription of the genes encoding IkBa and p105 and by stabilizing IkBa, v-Rel induces the formation of these complexes (HrdlickovaÂ et al., 1995b) . Curiously, the sizes of the cellular v-Rel-containing complexes (e.g., 300 ± 400 kDa) suggest that the v-Rel complexes are greater than dimeric complexes (e.g., larger than vRel ± p105, v-Rel ± p100, etc.) or that v-Rel complexes associate with other cellular proteins. Along these lines, Morrison et al. (1989) identi®ed an approximate 200 kDa polypeptide in immunoprecipitates of nuclear fractions from a v-Rel-transformed lymphoid cell line and v-Rel immunoprecipitates contain a serine-speci®c kinase activity that has not been precisely identi®ed (Gilmore and Temin, 1986; Tung et al., 1998a,b; Walro et al., 1987) .
v-Rel also interacts more transiently and in a weaker manner with several other cellular proteins, which are not generally seen in v-Rel immunoprecipitates but which may actually be more important for its transforming activity. In particular, many of these interactions may be important for the ability of v-Rel to activate transcription, and as such, include interactions with basal transcription factors (TBP and TFIIB) (Xu et al., 1993) , a transcriptional co-activator (Trip6) (Koedood Zhao et al., 1999) , and Sp1 (Sif and Gilmore, 1994; .
Other activities of v-Rel
Although much work has concentrated on the DNAbinding and transcription regulatory properties of vRel, there are other activities that may be relevant to its transforming ability. At least one study has shown that v-Rel can directly stimulate DNA replication. That is, it was shown that v-Rel (and other Rel/NF-kB family members also) can stimulate DNA replication of polyoma virus. This activity mapped to the RH domain and required the ability of v-Rel to bind to kB sites in polyoma virus DNA. However, it is not known whether this DNA replication enhancing acitivity of v-Rel can act on cellular DNA. In addition, the protein kinase activity that associates with v-Rel-containing cellular complexes (Gilmore and Temin, 1986; Rice et al., 1986; Simek et al., 1986; Tung et al., 1988a,b; Walro et al., 1987) has not been identi®ed, and it is possible that vRel alters the activity of this kinase. Lastly, although most data indicate that v-Rel blocks dierentiation of avian lymphoid cells, v-Rel can induce the differentiation of P19 embryonal carcinoma cells (Inuzuka et al., 1994) .
Post-translational modi®cations of v-Rel
v-Rel can undergo a variety of post-translational modi®cations. However, in most cases, the biological or biochemical relevance of these modi®cations is not known. Sachdel & Hannink, 1998 Sachdev & Hannink, 1998 Several studies have shown that v-Rel is a phosphoprotein in transformed chicken spleen cells and ®broblasts, and that it is phosphorylated at serine and, to a lesser extent, threonine residues (Gilmore and Temin, 1986; Lim et al., 1990; Moore and Bose, 1988b; Mosialos et al., 1991; Rice et al., 1986; Storms and Bose, 1992; Tung et al., 1998a,b; Walro et al., 1987) . In transformed spleen cells, okadaic acid and zinc can induce phosphorylation of v-Rel (Mosialos et al., 1991; Storms and Bose, 1992) , and both nuclear and cytoplasmic forms of v-Rel are phosphorylated (Davis et al., 1990) . Moreover, several early studies showed that v-Rel could be co-precipitated with a serinespeci®c protein kinase activity (Gilmore and Temin, 1986; Rice et al., 1986; Simek et al., 1986; Tung et al., 1988a,b; Walro et al., 1987) ; however, the identity of this kinase is still not known. Curiously, incubation of v-Rel immune complexes from transformed spleen cells with radiolabeled ATP resulted in phosphorylation of both v-Rel and what is now known to be IkBa (Tung et al., 1988b) . One wonders whether the formerly elusive IkB kinase (IKK) is present in such complexes (see Karin, 1999, this issue) .
Peptide mapping indicates that there are at least nine phosphorylation sites within v-Rel (Mosialos et al., 1991) . The only phosphorylation site that has been studied in any detail is a conserved, consensus protein kinase A recognition site within the RH domain of vRel and chicken c-Rel (Arg-Arg-Pro-Ser; Ser-275 in vRel and Ser-266 in c-Rel). This Ser can be phosphorylated by puri®ed PKA in vitro, and v-Rel is phosphorylated at Ser-275 in transformed cells (Mosialos et al., 1991) . Mutation of Ser-275 to an Ala, Thr or Trp residue does not appreciably aect DNA binding or transformation by v-Rel, indicating that this Ser residue need not be phosphorylated for these important activities. However, mutations that replace Ser-275 with phosphorylation site mimetics (Glu or Asp) greatly reduce the dimerization, DNA binding and transforming activities of v-Rel (Mosialos et al., 1991; Mosialos and Gilmore, 1993) . This ®nding suggests that phosphorylation of Ser-275 might negatively regulate v-Rel (or other Rel family proteins containing this site), possibly by aecting the formation of homodimers; however, there is no direct evidence for this hypothesis. In contrast to v-Rel, DNA binding by c-Rel is severely aected by all mutations (Ser to Ala, Glu, Asp, Trp) at Ser-266 (Mosialos et al., 1991; Mosialos and Gilmore, 1993) . In part, the dierential sensitivity of v-Rel and c-Rel to mutations at this Ser residue is due to a second nearby mutation (the Glu to Ala mutation at aa 278 in v-Rel) (Mosialos and Gilmore, 1993) ; it is likely that the mutation at aa 278 in v-Rel enables v-Rel to form more stable homodimers than c-Rel.
Partial proteolysis studies indicate that most of the phosphorylated serine residues are in the C-terminal half of v-Rel (Mosialos, 1993) , which overall is quite serine-rich. These sites of phosphorylation have not been mapped. However, have substituted Ala residues for many of these C-terminal serines. Most of these Ala substitutions did not aect either the transactivating or transforming activities of v-Rel, however, three sites were notably aected. In two cases, Ser to Ala mutations at residues 398/399 or 402 greatly reduced transactivation and transformation, whereas Ser to Asp mutations at these sites did not aect these activities. In a third case, simultaneous Ser to Ala mutations at aa 438 and 439 reduced transactivation and transformation, but while Ser to Asp mutations at these sites restored transactivating activity, they did not restore transforming activity. The Ser438/439Asp mutant is quite intriguing for several reasons: it suggests that phosphorylation of these sites would abolish the transforming function of v-Rel; and it represents the only C-terminal mutation which does not show a correlation between transactivation and transformation. Of note, a GAL4 fusion protein containing the C-terminal sequences of the Ser438/ 439Asp mutant can activate transcription in yeast, whereas the same GAL4 fusion containing wild-type or Ser to Ala mutant sequences cannot (Gilmore TD, Dooher JE and Wang Y, unpublished results) , suggesting that it may be possible to identify a kinase for these sites using a yeast genetic screen.
Caspases comprise a family of evolutionarily conserved cysteine proteases, many of which act as eectors of apoptosis by cleaving various substrate proteins C-terminal to Asp residues that fall within speci®c consensus cleavage sites (reviewed in NunÄ ez et al., 1998). Caspase-3 is one of the major cell-death eector caspases in vertebrates. Recently, have shown in vitro that v-Rel is resistant to proteolysis by caspase-3 due to three mutations. That is, the C-terminal deletion in v-Rel has removed one caspase-3 cleavage site and two point mutations in vRel (the Asp to Gly mutation at aa 91 of v-Rel and the Asp to Asn mutation at aa 437) have abolished caspase-3 cleavage sites. Consistent with this, v-Rel is quite stable when temperature-sensitive v-Rel-transformed cells are induced to undergo apoptosis and cellular substrates undergo caspase-mediated cleavage White et al., 1995) . However, the biological relevance of caspase-3 resistance for v-Rel is not known. v-Rel also contains possible sites of oxidation, glycosylation, and ubiquitination; however, these have been less well-characterized than the modi®cations described above. Although there are three potential N-linked glycosylation sites in v-Rel (Asn-52, Asn-170 and Asn-437), eorts to detect a glycosylated form of v-Rel have not been successful . Similarly, although a conserved Cys residue (Cys-35) within a sequence critical for DNA binding has been shown to undergo redox regulation in vitro , there is no substantial evidence that v-Rel (or other Rel proteins) undergo such regulation in vivo. Finally, Chen et al. (1998) have recently suggested that v-Rel undergoes reduced ubiquitin-proteasomemediated degradation as compared to c-Rel.
Cooperation between v-Rel and other oncogenic factors
There have been few studies that have identi®ed cooperating factors for v-Rel-mediated oncogenesis. This is no doubt because v-Rel is so devastatingly oncogenic in birds and eciently transforming in avian lymphoid cells, and yet toxic in many mammalian cell systems which are more amenable to genetic cooperation studies.
GeÂ linas and Temin (1998) showed that v-Rel could enhance the ability of polyoma middle T-antigen to transform rodent ®broblasts. However, in retrospect, this was probably not due to oncogenic cooperation per se, but rather to an eect of v-Rel on kB sites in the promoter controlling middle T-antigen expression in those cells.
Using retroviral vectors for the co-expression of vRel mutants and other proteins, were able to show oncogenic cooperation between certain v-Rel mutants and Bcl-2 for chicken spleen cell transformation. In particular, the oncogenicity of a weakly oncogenic mutant of v-Rel was enhanced over 40 times by co-expression of Bcl-2, even though Bcl-2 could not transform these cells by itself. The smaller eect of Bcl-2 on transformation by wild-type v-Rel was likely a re¯ection of the already near maximal transforming eciency of wild-type v-Rel in these assays. Of note, several human lymphoid cancers that have primary alterations in c-rel structure or expression also have alterations in bcl-2. Thus, the identi®cation of genes that enhance the oncogenicity of attenuated vrel mutants may provide insight into the types of oncogenic cooperation that may occur in human cancers that express mutant Rel transcription factors.
Summary
Unlike mnay other retroviral oncogenes, there has been a single virus isolate containing a transforming rel gene. As a consequence of extensive mutations in Relderived and viral sequences (Table 3) , Rev-T has developed into a highly ecient and lethal transforming agent. As such, it will be quite interesting to compare the x-ray crystallographic structures of v-Rel and c-Rel. Thus, the chimeric v-Rel protein is a mischievous sibling in the Rel/NF-kB family, whose extreme oncogenicity arises in large part from its ability to escape the normal regulatory constraints on these factors, to enter the nucleus, and to chronically promote the expression of genes that induce proliferation and block apoptosis. The mechanism by which vRel causes oncogenesis may not be strictly analogous to the role that mutant or mis-regulated cellular Rel/ NF-kB factors play in human cancers (see Rayet and GeÂ linas, 1999, this issue) . Nevertheless, v-Rel provides the only consistent model for studying Rel-mediated oncogenesis in vivo and in vitro. Therefore, the study of v-Rel will likely continue to play a key role in the development of model systems for understanding human cancers that have mis-regulations in the Rel/ NF-kB signal transduction pathway.
